Cargando…

Current role of prostate-specific membrane antigen-based imaging and radioligand therapy in castration-resistant prostate cancer

Castration-resistant prostate cancer (CRPC) is a therapy-resistant and lethal form of prostate cancer as well as a therapeutic challenge. Prostate-specific membrane antigen (PSMA) has been proved as a promising molecular target for optimizing the theranostics for CRPC patients. When combined with PS...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Jiaxian, Qi, Lin, Tang, Yongxiang, Tang, Guyu, Gan, Yu, Cai, Yi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Cell and Developmental Biology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9411749/ https://www.ncbi.nlm.nih.gov/pubmed/36036001 http://dx.doi.org/10.3389/fcell.2022.958180

Ejemplares similares

Narrative review: prostate-specific membrane antigen-radioligand therapy in metastatic castration-resistant prostate cancer
por: Lunger, Lukas, et al.
Publicado: (2021)

Identifying a Ferroptosis-Related Gene Signature for Predicting Biochemical Recurrence of Prostate Cancer
por: Lv, Zhengtong, et al.
Publicado: (2021)

Current status of radioligand therapy and positron-emission tomography with prostate-specific membrane antigen
por: Inubushi, Masayuki, et al.
Publicado: (2020)

Radioligand therapy of metastatic castration-resistant prostate cancer: current approaches
por: Awang, Zool Hilmi, et al.
Publicado: (2018)

Renal outcomes of radioligand therapy: experience of (177)lutetium—prostate-specific membrane antigen ligand therapy in metastatic castrate-resistant prostate cancer
por: Gallyamov, Marat, et al.
Publicado: (2019)

Synergistic Interaction of Histone Deacetylase 6- and MEK-Inhibitors in Castration-Resistant Prostate Cancer Cells
por: Corno, Cristina, et al.
Publicado: (2020)

Natural Products for the Management of Castration-Resistant Prostate Cancer: Special Focus on Nanoparticles Based Studies
por: Singla, Rajeev K., et al.
Publicado: (2021)

Prostate-Specific Membrane Antigen (PSMA) Promotes Angiogenesis of Glioblastoma Through Interacting With ITGB4 and Regulating NF-κB Signaling Pathway
por: Gao, Yang, et al.
Publicado: (2021)

PIP5K1α is Required for Promoting Tumor Progression in Castration-Resistant Prostate Cancer
por: Wang, Tianyan, et al.
Publicado: (2022)

Circulating Tumour Cells Indicate the Presence of Residual Disease Post-Castration in Prostate Cancer Patient-Derived Xenograft Models
por: Hassan, Sara, et al.
Publicado: (2022)

Lutetium-177-Labeled Prostate-Specific Membrane Antigen-617 for Molecular Imaging and Targeted Radioligand Therapy of Prostate Cancer
por: Ritawidya, Rien, et al.
Publicado: (2023)

Prostate-specific membrane antigen (PSMA)–ligand positron emission tomography and radioligand therapy (RLT) of prostate cancer
por: Tateishi, Ukihide
Publicado: (2020)

Efficacy and Haematologic Toxicity of Palliative Radioligand Therapy of Metastatic Castrate-Resistant Prostate Cancer with Lutetium-177-Labeled Prostate-Specific Membrane Antigen in Heavily Pre-Treated Patients
por: Kesavan, Murali, et al.
Publicado: (2021)

Explorative analysis of a score predicting the therapy response of patients with metastatic, castration resistant prostate cancer undergoing radioligand therapy with (177)Lu-labeled prostate-specific membrane antigen
por: Huang, Kai, et al.
Publicado: (2020)

Prostate-Specific Membrane Antigen Uptake and Survival in Metastatic Castration-Resistant Prostate Cancer
por: Vlachostergios, Panagiotis J., et al.
Publicado: (2021)

Regulatory Roles of Six-Transmembrane Epithelial Antigen of the Prostate Family Members in the Occurrence and Development of Malignant Tumors
por: Chen, Wen-Jia, et al.
Publicado: (2021)

RUNX1 marks a luminal castration-resistant lineage established at the onset of prostate development
por: Mevel, Renaud, et al.
Publicado: (2020)

The Identification of Plasma Exosomal miR-423-3p as a Potential Predictive Biomarker for Prostate Cancer Castration-Resistance Development by Plasma Exosomal miRNA Sequencing
por: Guo, Tianyu, et al.
Publicado: (2021)

Treatment of Advanced Metastatic Prostate Cancer Using Molecular-Targeted Therapy: Radioligand Lutetium-177 Prostate-Specific Membrane Antigen
por: Rathore, Rajni, et al.
Publicado: (2023)

Perspectives on Circular RNAs as Prostate Cancer Biomarkers
por: Fang, Jiajie, et al.
Publicado: (2020)

Differential Expression of E2F Transcription Factors and Their Functional and Prognostic Roles in Human Prostate Cancer
por: Han, Zhaodong, et al.
Publicado: (2022)

Focus on the tumor microenvironment: A seedbed for neuroendocrine prostate cancer
por: Zhou, Hengfeng, et al.
Publicado: (2022)

Deepening of response to prostate-specific membrane antigen ligand-targeted radioligand therapy beyond end of treatment
por: Derlin, Thorsten, et al.
Publicado: (2021)

Androgen Receptor-Related Non-coding RNAs in Prostate Cancer
por: Yang, Yongyong, et al.
Publicado: (2021)

Integrative Epigenome Map of the Normal Human Prostate Provides Insights Into Prostate Cancer Predisposition
por: Wang, Tao, et al.
Publicado: (2021)

The Role of Androgen Receptor in Cross Talk Between Stromal Cells and Prostate Cancer Epithelial Cells
por: Tang, Qianyao, et al.
Publicado: (2021)

Efficacy and Safety of Actinium-225 Prostate-Specific Membrane Antigen Radioligand Therapy in Metastatic Prostate Cancer: A Systematic Review and Metanalysis
por: Parida, Girish Kumar, et al.
Publicado: (2023)

Editorial: The development of lethal prostate cancer
por: Zhang, Baotong, et al.
Publicado: (2023)

Comparison of a Personalized Prostate Biopsy Pattern With Traditional Transrectal Prostate Biopsy: Different Cancer Detection Rate
por: Jiang, Xin, et al.
Publicado: (2022)

Should Lutetium-prostate specific membrane antigen radioligand therapy for metastatic prostate cancer be used earlier in men with lymph node only metastatic prostate cancer?
por: Yaxley, William John, et al.
Publicado: (2021)

Prostate-specific Membrane Antigen Based Antibody-drug Conjugates for Metastatic Castration-resistance Prostate Cancer
por: Niaz, Muhammad O, et al.
Publicado: (2020)

Tumor Suppressive Maspin-Sensitized Prostate Cancer to Drug Treatment Through Negative Regulating Androgen Receptor Expression
por: Tang, Sijie, et al.
Publicado: (2020)

Registered report: the androgen receptor induces a distinct transcriptional program in castration-resistant prostate cancer in man
por: Chronscinski, Denise, et al.
Publicado: (2015)

Potential application of lutetium-177-labeled prostate-specific membrane antigen-617 radioligand therapy for metastatic castration-resistant prostate cancer in a limited resource environment: Initial clinical experience after 2 years
por: Assadi, Majid, et al.
Publicado: (2020)

Genome-Scale CRISPR-Cas9 Transcriptional Activation Screening in Metformin Resistance Related Gene of Prostate Cancer
por: Chen, Jiahong, et al.
Publicado: (2021)

Isoalantolactone Increases the Sensitivity of Prostate Cancer Cells to Cisplatin Treatment by Inducing Oxidative Stress
por: Huang, Hang, et al.
Publicado: (2021)

Intermittent Radioligand Therapy with (177)Lu-PSMA-617 for Oligometastatic Castration-Resistant Prostate Cancer
por: Mader, Nicolai, et al.
Publicado: (2023)

MicroRNA-1205 Regulation of FRYL in Prostate Cancer
por: Naidoo, Michelle, et al.
Publicado: (2021)

The epigenetic function of androgen receptor in prostate cancer progression
por: Sawada, Takahiro, et al.
Publicado: (2023)

T Cell Membrane Heterogeneity Aids Antigen Recognition and T Cell Activation
por: Farrell, Megan V., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_obajvpolmi99p0jsrjhs0q788s